Programme of the “10th Berlin Conference on Life Sciences – Novel Antimicrobials”
Time | Title | |
---|---|---|
09:00 – 09:30 | Registration | |
09:30 – 09:45 | Welcome address Nick Leake, Counsellor and Head of the EU & Economic Section at the British Embassy Berlin | |
Keynote Session | ||
09:45 – 10:10 | Keynote: The Global AMR Innovation Fund Christopher Egerton-Warburton, Fund Manager and Founding Partner of Lion's Head Global Partner and Member of Expert Advisory Bord, Global AMR Innovation Fund > PPT > CV | |
10:10 – 10:30 | Stimulating innovation: novel approaches to incentivising antibacterial R&D David Findlay, Deputy Coordinator Drive-AB/GSK, UK > PPT > CV | |
10:30 – 10:50 | Funding the research and development of novel antibiotics: the perspective of a startup company Nicholas Benedict, Co-Founder & CEO, Allecra, GER > PPT > CV | |
10:50 – 11:10 | Coffee Break | |
Session "Market access in the era of AMR - bringing ideas to the patients" | Session “SMEs to tackle AMR” Chair: Philippe Villain-Guillot, CEO, Nosopharm - Leonie de Best, CBO, Madam Therapeutics, NL > PPT > CV - Philippe Villain-Guillot, CEO, Nosopharm > PPT > CV - Marc Lemonnier, CEO, Antabio, F > PPT > CV - Thomas Kapsner, CEO Morphochem, GER > PPT > CV | |
11:10 – 11:40 | Intellectual Property Rights and their Role in fostering Creation and Distribution of Innovations Heinz Goddar (Partner), Boehmert & Boehmert, GER > PPT > CV | |
Compulsory Licenses – Bliss or Doom for Pharmaceutical Industry Ute Kilger (Partner), Boehmert & Boehmert, GER > PPT > CV | ||
11:40 – 12:00 | From bench to bedside: Developing new drugs for bad bugs on a European scale Anders Karlén, University of Uppsala, SE and Managing Coordinator, ENABLE consortium > PPT > CV | |
12:00 – 12:20 | Clinical decision making: The relevance of new methods for antimicrobial susceptibility testing Hajo Grundmann, University of Groningen, Member of EUCAST Subcommittee, NL > PPT > CV | |
12:20 – 12:50 | Panel discussion – How to overcome the bottlenecks in the AMR field? Christopher Egerton-Warburton, Member of Expert Advisory Bord, Global AMR Innovation Fund > CV Andrew Ullmann, University of Würzburg > CV Ute Kilger, Boehmert & Boehmert > CV Hajo Grundmann, University of Groningen > CV | |
12:50 – 13:40 | Lunch Break | |
Session “How to create a business case with antimicrobials” | Session: Think beyond – technology highlights from academic research Chair: Andrew Ullmann, University of Würzburg - Yves Briers, Ghent University, BE > PPT > CV - Stephan Sieber, Technical University Munich, GER > CV - Michael McDonough, University of Oxford, UK > PPT > CV - Mark Brönstrup, Helmholtz Centre for Infection Research, GER > CV - Andreas Peschel, University of Tübingen, GER > PPT > CV | |
13:40 – 14:00 | Accelerating the antibiotics pipeline: CARB-X and AMRC Peter Jackson, steering group chairman, AMR centre, UK > PPT > CV | |
14:00 – 14:20 | Reliability of antibiotics supply in Germany – Effect of supplier consolidation Morris Hosseini, Roland Berger, GER > PPT | |
14:20 – 14:40 | The SME perspective Marie Petit, Coordinator, BEAM Alliance Sergio Lociuro, CSO, BioVersys, CH > PPT > CV1 > CV2 | |
14:40 – 15:40 | Technology Highlights Rasmus Toft-Kehler, CEO, AntibioTx, DK > PPT > CV Deborah O’Neil, CEO & CSO, NovaBiotics, UK > PPT > CV Frauke Hein, CBO, Adrenomed AG, GER > PPT > CV | |
15:40 – 16:10 | Coffee Break | |
Session “Start-up competition & investors talk” | ||
16:10 – 16:40 | Investors talk – Panel Discussion: Developing new antimicrobial agents - a business case for start-ups? Holger Reithinger, Partner, Forbion Capital Partners, GER/NL Sergio Lociuro, CSO, BioVersys, CH Rasmus Toft-Kehler, CEO, AntibioTx, DK Olivier Litzka, Partner, Edmond de Rothschild, F > CVs | |
16:40 – 17:20 | Start-up pitch: Start-up presentations and award Auspherix, UK > PPT > CV Immunethep, P > PPT > CV Juvabis, CH > PPT > CV QureTech Bio, S > PPT > CV Omnix Medical, ISR > PPT > CV | |
17:20 – 17:40 | Open discussion and wrap-up: The future of antiinfective R&D | |
17:40 – 19:00 | Networking & reception |
Moderator: Peter West, CEO, Academy of Infection Management (AIM)
> CV
Download the conference materials